MDM2 and B-cell chronic lymphocytic leukemia: The functional integrity of the p53 signaling pathway was evaluated by treating CLL cells with the MDM2-p53 antagonist HDM201 for 24 h and assessing the protein expression of p53 transcriptional target genes.